A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Inclusion Criteria: * Participants with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAF V600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a Deoxyribonucleic acid (DNA) sequencing method, and who have no acceptable standard treatment options * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * Life expectancy of greater than or equal to (\>/=) 12 weeks * Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment * Adequate hematologic and end organ function * Female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use 2 effective methods of contraception * Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential Exclusion Criteria: * Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose of study drug * Requirement for immediate or urgent treatment with daily vemurafenib and for whom the intermittent schedule of vemurafenib employed during the 24-day period for this trial is not clinically acceptable * Allergy or hypersensitivity to components of the vemurafenib formulation * Experimental therapy within 4 weeks prior to first dose of study drug * Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug, or anticipation of the need for major surgery during study treatment * Prior anti-cancer therapy within 28 days before the first dose of study drug * History of clinically significant cardiac or pulmonary dysfunction * History of symptomatic congestive heart failure of any New York Heart Association class or serious cardiac arrhythmia requiring treatment * History of myocardial infarction within 6 months prior to first dose of study drug * Current dyspnea at rest, owing to complications of advanced malignancy or any requirement for supplemental oxygen to perform activities of daily living * History of congenital long QT syndrome or corrected QT interval (QTc) greater than (\>) 450 milliseconds * Active central nervous system lesions * Uncontrolled or poorly controlled diabetes * Current severe, uncontrolled systemic disease